Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/99364
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Saladores, P. | - |
dc.contributor.author | Muerdter, T. | - |
dc.contributor.author | Eccles, D. | - |
dc.contributor.author | Chowbay, B. | - |
dc.contributor.author | Zgheib, N. | - |
dc.contributor.author | Winter, S. | - |
dc.contributor.author | Ganchev, B. | - |
dc.contributor.author | Eccles, B. | - |
dc.contributor.author | Gerty, S. | - |
dc.contributor.author | Tfayli, A. | - |
dc.contributor.author | Lim, J. | - |
dc.contributor.author | Yap, Y. | - |
dc.contributor.author | Ng, R. | - |
dc.contributor.author | Wong, N. | - |
dc.contributor.author | Dent, R. | - |
dc.contributor.author | Habbal, M. | - |
dc.contributor.author | Schaeffeler, E. | - |
dc.contributor.author | Eichelbaum, M. | - |
dc.contributor.author | Schroth, W. | - |
dc.contributor.author | Schwab, M. | - |
dc.contributor.author | et al. | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | The Pharmacogenomics Journal, 2015; 15(1):84-94 | - |
dc.identifier.issn | 1470-269X | - |
dc.identifier.issn | 1473-1150 | - |
dc.identifier.uri | http://hdl.handle.net/2440/99364 | - |
dc.description.abstract | Tamoxifen is the standard-of-care treatment for estrogen receptor-positive premenopausal breast cancer. We examined tamoxifen metabolism via blood metabolite concentrations and germline variations of CYP3A5, CYP2C9, CYP2C19 and CYP2D6 in 587 premenopausal patients (Asians, Middle Eastern Arabs, Caucasian-UK; median age 39 years) and clinical outcome in 306 patients. N-desmethyltamoxifen (DM-Tam)/(Z)-endoxifen and CYP2D6 phenotype significantly correlated across ethnicities (R²: 53%, P<10⁻⁷⁷). CYP2C19 and CYP2C9 correlated with norendoxifen and (Z)-4-hydroxytamoxifen concentrations, respectively (P<0.001). DM-Tam was influenced by body mass index (P<0.001). Improved distant relapse-free survival (DRFS) was associated with decreasing DM-Tam/(Z)-endoxifen (P=0.036) and increasing CYP2D6 activity score (hazard ratio (HR)=0.62; 95% confidence interval (CI), 0.43–0.91; P=0.013). Low (<14 nM) compared with high (˃435 nM) endoxifen concentrations were associated with shorter DRFS (univariate P=0.03; multivariate HR=1.94; 95% CI, 1.04–4.14; P=0.064). Our data indicate that endoxifen formation in premenopausal women depends on CYP2D6 irrespective of ethnicity. Low endoxifen concentration/formation and decreased CYP2D6 activity predict shorter DRFS.. | - |
dc.description.statementofresponsibility | P Saladores, T Mürdter, D Eccles, B Chowbay, NK Zgheib, S Winter, B Ganchev, B Eccles, S Gerty, A Tfayli, JSL Lim, YS Yap, RCH Ng, NS Wong, R Dent, MZ Habbal, E Schaeffeler, M Eichelbaum, W Schroth, M Schwab and H Brauch | - |
dc.language.iso | en | - |
dc.publisher | Nature Publishing Group: Open Access Hybrid Model Option B | - |
dc.rights | © 2015 Macmillan Publishers Limited All rights reserved | - |
dc.source.uri | http://dx.doi.org/10.1038/tpj.2014.34 | - |
dc.subject | Tamoxofin | - |
dc.title | Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1038/tpj.2014.34 | - |
pubs.publication-status | Published | - |
Appears in Collections: | Aurora harvest 3 Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.